Krill Oil and Resistance Exercise in Older Adults

Sarcopenia Clinical Trial

— KOREA  

Official title:

The Effects of Krill Oil Supplementation on Adaptations in Muscle Strength, Function, Mass and Neuromuscular Function to a Pragmatic Home-based Resistance Exercise Intervention in Sedentary Older Adults: a Randomised Controlled Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05869513
• Other study ID #: KOREA
• Status: Recruiting
• Phase: N/A
• Start date: May 5, 2023
• Est. completion date: February 1, 2024

Study information

• Verified date: May 2023
• Source: University of Glasgow
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to determine whether krill oil supplementation enhances effects of a pragmatic resistance exercise programme on adaptations in muscle strength, mass, function and neuromuscular function in sedentary older adults. Hypothesis - krill oil supplementation will enhance the beneficial effects of resistance exercise on muscle strength, function, mass and neuromuscular function in sedentary older adults.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: February 1, 2024
• Est. primary completion date: February 1, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 60 Years to 90 Years

Eligibility

Inclusion Criteria:

• Over the age of 60 years

• scoring a low level of physical activity based on international physical activity questionnaire (not meeting the recommend physical activity which is at least 600 MET-min per week).

Exclusion Criteria:

• Diabetes

• severe cardiovascular disease

• seizure disorders

• uncontrolled hypertension (>150/90mmHg at baseline measurement)

• cancer or cancer that has been in remission <5 years

• ambulatory impairments which would limit ability to perform assessments of muscle function

• dementia

• taking medication known to affect muscle (e.g. steroids)

• have an implanted electronic device (e.g. pacemaker/defibrillator/insulin pump)

• on anticoagulant therapy

• allergies to seafood

• regular consumption of more than 1 portion of oily fish per week

• already taking fish or krill oil or other n3 PUFA supplements

• femoral neck fracture or other severe of hip or knee operations

• stroke

• Parkinson's disease

• COPD

• kidney disease

• hyperlipidaemia

• obesity

• osteoporosis.

Related Conditions & MeSH terms

• Sarcopenia

Intervention

Dietary Supplement:
• Vegetable oil
Mixed vegetable oil
• Krill oil
Superba Krill Oil

Other:
• Home-based resistance exercise
Home based resistance band and body weight exercise

Locations

Country	Name	City	State
United Kingdom	University of Glasgow	Glasgow

Sponsors (1)

Lead Sponsor	Collaborator
University of Glasgow

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Step Time (sec)	Measured during a 4m walk using a gaitrite mat	Change from baseline to 16 weeks
Other	Cycle Time (sec)	Measured during a 4m walk using a gaitrite mat	Change from baseline to 16 weeks
Other	Step Length (cm)	Measured during a 4m walk using a gaitrite mat	Change from baseline to16 weeks
Other	Stride Length (cm)	Measured during a 4m walk using a gaitrite mat	Change from baseline to16 weeks
Other	H-H Base Support (cm)	Measured during a 4m walk using a gaitrite mat	Change from baseline to 16 weeks
Other	Single Support (%GC)	Measured during a 4m walk using a gaitrite mat	Change from baseline to 16 weeks
Other	Double Support (%GC)	Measured during a 4m walk using a gaitrite mat	Change from baseline to 16 weeks
Other	Swing (%GC)	Measured during a 4m walk using a gaitrite mat	Change from baseline to 16 weeks
Other	Stance (%GC)	Measured during a 4m walk using a gaitrite mat	Change from baseline to 16 weeks
Other	Step/ Extremity Ratio	Measured during a 4m walk using a gaitrite mat	Change from baseline to 16 weeks
Other	Toe In / Out (deg)	Measured during a 4m walk using a gaitrite mat	Change from baseline to 16 weeks
Other	Distance (cm)	Measured during a 4m walk using a gaitrite mat	Change from baseline to 16 weeks
Other	Ambulation Time (sec)		Change from baseline to 16 weeks
Other	Velocity (cm/sec)	Measured during a 4m walk using a gaitrite mat	Change from baseline to 16 weeks
Other	Mean Normalized Velocity	Measured during a 4m walk using a gaitrite mat	Change from baseline to16 weeks
Other	Number of Steps	Measured during a 4m walk using a gaitrite mat	Change from baseline to 16 weeks
Other	Cadence (Steps/Min)	Measured during a 4m walk using a gaitrite mat	Change from baseline to 16 weeks
Other	Step Time Differential (sec)	Measured during a 4m walk using a gaitrite mat	Change from baseline to 16 weeks
Other	Step Length Differential (cm)	Measured during a 4m walk using a gaitrite mat	Change from baseline to 16 weeks
Other	Cycle Time Differential (sec)	Measured during a 4m walk using a gaitrite mat	Change from baseline to 16 weeks
Primary	Nueromuscular Junction (NMJ) transmission instability	NMJ transmission instability will be measured by iEMG	Change from baseline to 16 weeks
Secondary	Knee extensor maximal torque	Knee extensor maximal torque will be measured by a load cell	Change from baseline to 8 16 weeks
Secondary	30s chair stand test	measuring the functional abilities	Change from baseline to 16 weeks
Secondary	Gait speed	measuring the functional abilities	Change from baseline to 16 weeks
Secondary	Force steadiness during submaximal isometric knee extensor contractions	Steadiness of force whilst contracting	Change from baseline to 16 weeks
Secondary	Red Blood Cell Omega-3 levels		Change from baseline to 16 weeks
Secondary	Grip strength	Grip strength will be measured by handgrip dynamometer	Change from baseline to 16 weeks
Secondary	Muscle thickness	Vastus Lateralis muscle thickness will be measured by ultrasound	Change from baseline to 16 weeks